Sunitinib, a multitargeted tyrosine kinase inhibitor, in the management of gastrointestinal stromal tumor.

Abstract excerpt

Due to the remarkable advances in the understanding of the biology of gastrointestinal stromal tumors (GIST), tyrosine kinase inhibition has become the mainstay of therapy for patients with advanced GIST. Sunitinib is a tyrosine kinase inhibitor with a wide range of kinase inhibition, including KIT, platelet-derived growth factor receptor (PDGFR), vascular endothelial growth factor (VEGF), and FLT3. Sunitinib has...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Drug Administration Schedule
• Share to fms-Like Tyrosine Kinase 3
• Share to Gastrointestinal Stromal Tumors